|
|
Sitemap
- Home
- About us
- Sitemap
- Contact us
- Forum
- Services
- Nanomedicine and Drug Delivery News
- Innocoll's Gentamicin Topical new human study commences
- Zelos and Aegis sign deal for Intravail(R) technology
- Jazz launches Luvox(R) CR
- Oramed starts phase 2a for oral insulin
- sNDA for RISPERDAL(R) CONSTA(R)
- Nektar terminates insulin programs
- Iomai receives grant to develop anthrax vaccine
- Aradigm starts trial using AERx technology
- Endo to return rights to CHRONOGESIC(R)
- Abraxis acquires Shimoda Biotech
- Iomai and Merck enter agreement to evaluate patch
- Indevus licenses VANTAS(R) to Orion
- Abraxis commences phase 2 of Coroxane(TM)
- Vivus reaches SPA agreement for Luramist(TM)
- Elite Pharmaceuticals updates data on pain products
- Acusphere licences HDDS(TM) to Cephalon
- QLT starts phase 2 study for punctal plug drug delivery system
- Teva will acquire Bentley
- Avanti launches a new drug delivery company
- IntelliPharmaCeutics completes clinical trial on ReXista(TM)
- Alexza forms subsidiary in Singapore
- Depomed starts phase 3 study of Gabapentin GR(TM)
- Zogenix files for IPO
- Biovail settles case with SEC
- Abbott receives rights to Lupron Depot(R)
- Emisphere updates data on oral B12
- BioSante initiates third phase 3 study for LibiGel(R)
- Alkermes restructures operations
- Alimera and pSivida amend deal on Medidur(TM)
- DiObex and Camurus sing license agreement
- NanoBio completes phase 2 trial of NB-001
- FDA reviews QLT's Aczone(TM)
- Baxter presents clinical results of subcutaneous GAMMAGARD LIQUID(TM)
- Silence Therapeutics and AstraZeneca to collaborate
- Innocoll commences second phase 2 trial of surgical implant
- Celsion starts phase 3 for ThermoDox(R)
- Abbott receives CE Mark for 2.25 mm XIENCE(TM) V DES
- Inovio reports data on malignant melanoma study
- Cerner and UNM enter deal to evaluate a DPI
- Halozyme presents PK data on new manufacturing process
- AVANT and Celldex complete merger
- Lilly terminates inhaled insulin agreement with Alkermes
- Penwest announces private placement
- NanoBio receives funding
- Notice from NASDAQ to Hana Biosciences
- Debio moves Debio 9902 SR forward
- MicroDose and Merck & Co. sign a deal
- Not approvable letter for Lilly's Zyprexa(R) LAI
- Arriva receives financing from Nordic Biotech
- NeurogesX reports results from phase 3 study of NGX-4010
- Galderma to acquire CollaGenex
- Organogenesis acquires NanoMatrix
- MacuSight reports preliminary results from phase 1 of sirolimus
- Javelin updates pharmacokinetic studies of PMI-150
- MonoSol Rx completes bioequivalence study for ondansetron film
- Sciele Pharma launches Fenoglide(TM)
- Oxford BioMedica continues TroVax(R) phase 3 studies
- Innocoll commences second phase 3 clinical trial of surgical implant
- Phosphagenics starts phase 1 study for its lead dermatological product
- Graceway Pharmaceuticals purchases Estrasorb(R)
- Diamyd to start clinical study with NP2
- Debiopharm presents data on Decapeptyl(R)/Trelstar(R) 6-month formulation
- Depomed reports data from phase 2 trial of Gabapentin GR(TM)
- Nastech to reduce workforce
- Nektar transforms into a drug development organization
- Unigene initiates phase 1/2 clinical trial for oral calcitonin
- Bentley reports preliminary results for Nasulin(R)
- Labopharm's once-daily trazodone meets endpoint
- SkyePharma to collaborate with Dr. Reddy's
- Alkermes repurchases $60 million
- Emisphere's vitamine B12 product to move ahead
- Lilly's long-acting Zyprexa(R) reviewed by FDA
- Alexza updates pipeline development status
- Forest reports positive results of once-daily memantine
- Penwest's Nalbuphine ER fails to meet primary endpoint
- Generex to start phase 3 study for Oral-lyn(TM)
- Vyteris redirects its business
- Acura's common stock to trade on NASDAQ
- Lux receives fast track designation for LX201
- IMPAX gets non-approvable letter for Vadova(R)
- BioSante completes SPA for LibiGel(R)
- SurModics extends collaboration deal with Merck & Co.
- Cephalon's EFFENTORA(TM) receives positive opinion from EMEA
- NovaDel's NDA for ZolpiMist(TM) filed
- NanoViricides to begin animal studies on FluCide(TM)
- Indevus reveals additional phase 3 data for NEBIDO(R)
- Oramed starts phase 1B study for oral insulin
- Vyteris reports clinical results of Smart Patch technology
- Abraxis receives European marketing approval for Abraxane(R)
- IVT recives $3 million funding
- VGX submits MAF for CELLECTRA(TM)
- QLT reduces workforce
- Biosensors receives CE Mark for BioMatrix(R)
- Novagali to start clinical program for ophthalmic drug
- YM BioSciences' AeroLEF(TM) on hold
- QLT seeks offers for the sale of QLT USA
- DelSite's nasal H5N1 influenza vaccine program advances
- Janssen-Cilag launches Ionsys(TM)
- ADVENTRX to file NDA for ANX-530
- Novo Nordisk discontinues inhaled insulin program
- Diamyd files IND for pain therapy
- Acusphere receives letter from NASDAQ
- Emergent BioSolutions advances its hepatitis B immunotherapy program
- Zogenix raises $18 million
- Amarin announces completion of nasal lorazepam study
- BioAlliance Pharma obtains market approval for Loramyc(R)
- Nektar starts two phase 2 clinical trials
- Recruitment complete of Nastech's PYY3-36 Nasal Spray
- Alizyme completes enrollment for COLAL-PRED(R) phase 3 clinical trial
- Watson reports positive results from study of oxybutynin gel
- Tacere and Pfizer to develop RNAi drug
- BioSante initiates LibiGel(R) safety study
- Alkermes closes commercialization agreement
- Innocoll commences US phase 2 clinical trial of surgical implant
- TAP files NDA for TAK-390MR
- Biodel completes enrollment of phase 3 clinical trials of VIAject(TM)
- Innocoll commences US phase 3 clinical trial of surgical implant
- NEOPHARM files IND for liposomal docetaxel
- IDM and sanofi-aventis end collaboration
- pSivida receives NASDAQ letter
- Flamel signs collaboration with Merck Serono
- Nektar and Baxter enter hemophilia agreement
- Bayer withdraws Viadur(R)
- Altus reacquires ALTU-238 rights from Genentech
- Cell Therapeutics to submit MAA for Xyotax(TM)
- Alexza completes patient enrollment in AZ-104 clinical trial
- DURECT reports positive ELADUR(TM) results
- BioSante receives milestone payment from Bradley
- Phosphagenics reports phase 1 results for transdermal oxycodone
- NanoPacific and CNSI announce partnership to commercialize nanoparticles for cancer
- Capsulated Systems develops anesthetic-loaded microparticles
- Alnylam and PARI report data on RSV treatment
- Ceregene presents data on CERE-120
- Devax announces completion of enrollment of DES trial
- Inovio to receive a milestone payment from Merck & Co.
- Javelin launches Dyloject(R)
- Copernicus receives milestone payment from Cystic Fibrosis Foundation
- Biovail to settle lawsuit
- Novo Nordisk settles with Pfizer on Exubera(R) suit
- ImmunoVaccine acquires Immunotope
- Acusphere reports clinical data on Imagify(TM)
- AlphaRx expands market in China
- Biojector(R) 2000 technology for Vaxfectin(TM) vaccine
- Nastech to develop a non-injectable dosage form of factor IX
- AVANT presents preclinical data on trivalent enteric vaccine
- InSite Vision files NDS with Health Canada
- ImmuneRegen and DelSite to combinate Homspera(TM) and GelSite(R)
- OncoVista licenses drug from OSI Pharmaceuticals
- Starpharma and Stiefel Laboratories enter agreement
- ImmunoVaccine Technologies scales-up the manufacturing process for Vaccimax(R)
- AMT and Digna Biotech to develop IGF-I product for liver cirrhosis
- Indevus announces positive results of phase 2 octreotide trial
- SP1049C to enter into phase 3 clinical trials
- QLT contemplates selling all or part of the company's assets
- Zogenix licenses opioid product from Elan
- Fovea and Genzyme sign a research agreement
- Oasmia licenses marketing rights of Paclical(R)
- PARI proclaims eFlow(R) inclusion in Gilead's NDA submission
- Orexo completes acquisition of Biolipox
- Biota commences LANI phase 2 clinical trials
- Tekmira to receive milestone payments
- Alkermes to repurchase shares of its common stock
- FDA accepts NDA for NexACT(R) product
- Hana Biosciences initiates phase 2 clinical trial of Marquibo(R)
- BioSante signs agreement with Medical Aesthetics Technology Corporation
- Aradigm initiates phase 2 clinical trial of ARD-3100
- Argos and Therakos, a Johnson & Johnson company, enter agreement
- Oramed's oral insulin to move ahead
- Nektar highlights research programs at R&D day
- Enrollment of phase 2 clinical trial evaluating CERE-120 completed
- Agreement on Exubera(R)
- Introgen submits first MAA for ADVEXIN(R)
- Halozyme Therapeutics to be added to NASDAQ Biotech Index
- Positive preclinical data support an IND file for VGX-3400
- Aktiv-Dry awarded SBIR research grant to investigate siRNA for treating RSV
- Biovail acquires rights for two early stage development drugs
- MannKind announces results from phase I of MKC253
- BioSante common stock commences trading on NASDAQ Global Market
- Seattle Genetics reports positive clinical data with antibody-drug conjugate product
- Acusphere's paclitaxel formulation offers partnership opportunities
- Biovail launches Ralivia(TM) in Canada
- BioDelivery Sciences reveals details regarding analgesic compounds
- Javelin receives first Marketing Authorization approval
- Merck Serono and EPFL set a new academic-industrial partnership
- Elan and Johnson & Johnson announce NDA submission for paliperidone palmitate
- Spotlights
- Company news: QLT's stock rises
- Pipeline news: Generex comments on oral insulin
- Company news: QLT's full-year 2007 results
- Company news: Elan's full-year 2007 revenues
- Research highlights: Block copolymeric nanofilms
- Research highlights: ABT627-loaded PLGA microspheres
- Company news: Latest news on Javelin Pharmaceuticals
- Pipeline news: FDA advisory panel reviews Abbott's XIENCE(TM) V
- Company news: Latest news on Nastech Pharmaceutical Company
- Research highlights: OctoPlus publishes data on IVIVC of hGH-loaded OctoDex(TM) microspheres
- Research highlights: The future of hydrogels
- Events
- Privacy policy
- FAQ
- Consulting
- DelScience News